Profile

Research

Publications

Team

Alumni

M Radhakrishna Pillai, FRCPath, PhD

Director/Professor

+91-471-2347973

mrpillai@rgcb.res.in

mrp
mrp

M Radhakrishna Pillai, FRCPath, PhD

Director/Professor

+91-471-2347973

mrpillai@rgcb.res.in

  • Profile

    • FRCPath, The Royal College of Pathologists, London
    • MRCPath, The Royal College of Pathologists, London
    • PhD Degree, University of Kerala, India
    • Fellow, Indian Academy of Sciences, Bangalore
    • Fellow, National Academy of Sciences, Allahabad
    • Fellow, National Academy of Medical Sciences
    • Chairman, Institutional Committee for Stem Cell Research, Sree Chitra Thirunal Institute of Medical Sciences & Technology, (Government of India), Thiruvananthapuram
    • Member, Governing Body of Translational Health Sciences & Technology Institute Society, (Government of India, Department of Biotechnology)
    • Member, Research Advisory Panel & Scientific Advisory Council, National Institute of Immunology, New Delhi (Government of India, Department of Biotechnology)
    • Member, Research Advisory Panel & Scientific Advisory Committee, National Centre for Cell Sciences, Pune (Government of India, Department of Biotechnology)
    • Member, Senate, University of Kerala
    • Member, Executive Committee, Kerala State Council for Science, Technology & Environment
    • Member, Kerala Biotechnology Commission and Kerala Biotechnology Board
    • Member, Kerala Innovation Council
    • Member, Academic Committee, Sree Chitra Thirunal Institute of Medical Sciences & Technology, (Government of India), Thiruvananthapuram.
    • 2003: National Bioscience Career Award, Department of Biotechnology, Government of India
    • 2000: Recipient of the Indian Council of Medical Research Sandoz Oration Award for Outstanding Cancer Research in the field of Human Papillomavirus Research
    • 1991: Recipient of the Indian Council of Medical Research Raja Ravi Sher Singh Award for outstanding Cancer Research by a young scientist in recognition for PhD work on “Development of an Immunological Staging System for cervical cancer”
    • Fellow, International Union Against Cancer (UICC)
    • Life Member, Indian Association for Cancer Research
    • Member, Indian Immunology Society
    • Member, Institute of Biology, London
    • Member, British Society of Immunology
    • Member, Indian Association of Biomedical Scientists
    • Twenty PhDs mentored to date all in academics or scientific positions
    • Nine ongoing PhD students
    • Patent titled "Novel porphyritic derivatives for photo dynamic therapy (PDT): A process for the preparation and thereof and their use as PDT agents and fluorescence probes for biological applications", D. Ramaiah, S. C. Karunakaran, V. S. Jisha, T. K. Chandrashekar, A. Sreenivasan, M. R. Pillai, S. A. Nair, S. B. P. Saras, C. M. Rao, K. S. Rao., Dated 14-Sep-2009 (Ref. No. 0147NF2009)
  • Research

    Our laboratory's focus is developing fundamental scientific discoveries in the laboratory or from population studies for improved strategies to eventually manage cancer better, reduce cancer incidence, morbidity and mortality. Our research programs have a good balance between computational, theoretical and "wet" laboratory protocols. We therefore work in research partnerships with teams comprising clinical oncologists, pathologists, biologists, chemists, engineers and bioinformaticians. All studies involving patients, tumor tissue and population studies are done through a joint Program of Excellence in Translational Research (PETR) with the Regional Cancer Centre.

    The laboratory has a unique combination of talented program scientists and post-doctoral trainees in addition to very vibrant students with diverse backgrounds ranging from medicine, veterinary pathology, biotechnology and bioinformatics. The laboratory is also privileged to host Dr Rakesh Kumar, Visiting Distinguished Professor of Biotechnology. We currently have major programs investigating the roles of infection and immunity in tumorigenesis besides understanding the underlying role of cancer stem like cells in disease progression and recurrence. We also manage an advanced facility for human papillomavirus (HPV) research that has a major program funded by the Bill & Melinda Gates Foundation through the International Agency for Research Against Cancer to look at immune responses to different doses of HPV vaccination and another program funded by the European Union to study differential infection by HPV in oro-pharyngeal tumor sub sites

    Ongoing PhD Theses at Regional Cancer Centre

    1. Dr. Paul Sebastian: Molecular ecology, molecular genetics and natural history of anterior tongue cancer in young adults without (or insignificant) tobacco exposure: can a distinct clinical entity be defined?
    2. Dr Elizabeth Iype: Biomarkers and treatment outcome for laryngeal cancer.

    Ongoing PhD Theses at RGCB

    1. Sumitra Shankar
    2. Sajitha I S
    3. Priya R Prabhu
    4. Rahul Sanawar
    5. Deepthi Prasad

    Ongoing Co-mentored theses at RGCB (with Professor Rakesh Kumar)

    1. Ms. Hezlin Marzook: MTA1 Regulation of an E3 Ligase RNF144A in Human Breast Cancer.
    2. Mr. Devindran R:Mechanism of MTA1 Overexpression-linked invasion: MTA1 Regulation of HMMR Expression and Function
    1. Pathobiological factors in cervical cancer.
      Dr. S. Lakshmi, 1998
    2. Histogenesis of carcinoma of the uterine cervix.
      Dr. S Asha Nair, 1998
    3. Programmed cell death in breast cancer.
      Dr. A. Lakshmi Kesari, 2000
    4. Cellular and molecular profile of Non Hodgkin's lymphoma in India.
      Dr. R. Radhakrishnan, 2000
    5. Programmed cell death, chemotherapy response and prognosis in pediatric acute lymphoblastic leukemia.
      Dr. G. Srinivas, 2002
    6. Molecular manifestations of tumor progression in the uterine cervix.
      Dr. Pradip Nair, 2002
    7. Viral and host gene polymorphism in Indian cervical cancer.
      Dr. Sreevidya. S, 2003
    8. Genetic polymorphisms of cancer susceptibility genes in Indian breast cancer.
      Dr Priya Chacko, 2004
    9. Influence of Genetic Polymorphisms on susceptibility to and treatment outcome in childhood acute lymphoblastic leukemia.
      Dr Thomas Joseph, 2004
    10. Matrix Metalloproteinases in oral cancer.
      Dr. Bindhu. O. S, 2005
    11. Molecular screening of curcumin and cleistanthin A as potential anti-human papillomavirus bioactive agents.
      Dr. Divya Chandrasekhar, 2007
    12. Apoptosis, radiosensitization and tumor cell response to radiation therapy in cervical cancer.
      Dr. Sreekala Nair, 2008
    13. Computational analysis of structure-function relations of human smads and its clinical relevance in cervical cancer.
      Dr. Ramkumar Hariharan, 2008
    14. Significance of DNA repair genes in oral cancer.
      Dr. Surya Ramachandran, 2009
    15. Clinical significance of Nuclear Factor Kappa B on epithelial tumorigenesis and minimal residual disease
      Dr Santhi WS, 2011
    16. The nutrigenomics of HPV associated tumor progression in the uterine cervix.
      Dr.Preethi NR, 2011
    17. Computational and functional analysis of microRNAs in cervical cancer
      Dr. Reshmi G, 2012
    18. Cell death and cell signaling pathways induced by sodium meta arsenite: significance as an anti-neoplastic agent
      Dr. Indhu Hariharan, 2012
    19. Cancer stem cells in oral tumorigenesis
      Dr. Vinitha Richard, 2012
    20. Molecular Epidemiology and treatment outcome in oral cancer
      Dr. K. Ramadas, 2013
    1. Accurate and satisfactory analysis of all high risk HPV types and some of the low risks including HPV 6 and 11 antibody titers for the 2-versus 3 dose HPV vaccination clinical trial in India. Joint Program between Rajiv Gandhi Centre for Biotechnology and International Agency for Research on Cancer, 2009-2016.
    2. Establishment of a National Virology Network Laboratory. Indian Council of Medical Research, 2011-2016.
    3. Role of human papillomavirus infection and other co-factors in the aetiology of head and neck cancer in Europe and India : HPV - AHEAD. Joint Program between Rajiv Gandhi Centre for Biotechnology and International Agency for Research on Cancer, 2011-2016.
    4. Whole genome survey of microRNA target site accessibility based on conserved local RNA secondary structure and protein binding site overlaps: Creating a Freely Accessible Web Resource. Department of Biotechnology, 2012-2015.
    5. Integrated computational analysis to drive discovery of micro RNA - medicated regulatory networks in HPV induced cervical cancer. Department of Biotechnology, 2013-2016.
    1. The University of Arizona Small Grants Program: Acquisition of PCFIA technology- The Fluorescence Analyzer and Concentrator.
    2. Role of cytostructural alterations in cervical carcinogenesis. Indian Council of Medical Research, 1992-1994.
    3. Clinical application of tumor growth fraction associated markers. Indian Council of Medical Research, 1993-1996.
    4. Growth factors in human tissue: relevance to tumor progression. Council for Scientific & Industrial Research, 1993-1996
    5. Human papillomavirus infection and epidermal growth factor in cervical carcinogenesis, Dept. of Science and Technology, 1992-1994.
    6. Detection and assessment of molecular markers associated with multidrug resistance in high grade Non-Hodgkin’s lymphoma. Indian Council for Medical Research, 1993-1996.
    7. Human papillomavirus infection and tissue pathology. Dept. of Atomic Energy, Govt. of India, 1993-1996.
    8. Development of a cell kinetic model to predict response to radiation therapy in cervical carcinoma. International Atomic Energy Agency, 1993-1996.
    9. Growth factors in pancreatic malignancy. Kerala State Committee for Science, Technology & Environment, 1993-1996
    10. Cellular manifestations of p53 and bcl-2 expression in ovarian cancer. Indian Council for Medical Research, 1996-1998.
    11. The mutant p53 protein in breast cancer. Kerala State Committee for Science, Technology & Environment, 1996-1999.
    12. Radiosensitivity, treatment outcome and ras gene mutation in rectal carcinoma. Dept. of Atomic Energy, Govt. of India, 1996-1999.
    13. Tumor response to radiation therapy in carcinoma of the uterine cervix : the role of ras gene mutation. Indian Council for Medical Research, 1996-2000.
    14. Programmed tumor cell death and proliferative fraction ratio in the staging of thyroid cancer. Indian Council for Medical Research, 1997-1999.
    15. Molecular regulation of programmed cell death. Dept. of Science & Technology, Govt. of India, 1997-2000.
    16. Telomere dynamics, telomerase activation and epithelial tumor progression. Council for Scientific & Industrial Research, Govt. of India, 1997-2000.
    17. Cellular immortality and apoptosis during tumor progression in the uterine cervix. Indian Council for Medical Research, 1999-2001.
    18. Programmed tumor cell death and proliferative fraction ratio in the staging of breast cancer. Kerala State Committee for Science,
      Technology & Environment, 1999-2001.
    19. Cellular immortality and de novo apoptosis in tumor tissue: significance for response to radiotherapy for cervical cancer.
      Dept. of Atomic Energy, Govt. of India, 1999-2002.
    20. Susceptibility to childhood acute lymphoblastic leukemia : influence of CYP1A1, CYP2D6, GSTM1 & GSTT1 genetic polymorphisms.
      Council of Scientific and Industrial Research, 1999-2003.
    21. Significance of programmed cell death in pediatric acute lymphoblastic leukemia. Dept of Science & Technology, Govt. of India, 1999-2003.
    22. Genotyping of the CYP1A1 and GSTM1 genes in tobacco associated oral cancer. Indian Council for Medical Research, 2000-2003.
    23. Metalloproteinase gene activation during tumor progression in the oral mucosa. Indian Council for Medical Research, 2000-2003.
    24. The role of telomere fragment lengths and telomerase activation during tumor progression in the uterine cervix. Kerala State Committee for Science, Technology & Environment, 1999-2003.
    25. Estrogen receptor gene polymorphism in Indian breast cancer and response to tamoxifen treatment. Kerala State Committee for Science, Technology & Environment, 1999-2003.
    26. Chemotherapy response in osteosarcoma: role of intrinsic cellular factors. Indian Council for Medical Research, 2001 – 2003.
    27. Polymorphism in CYP1A1, GSTM1 and XRCC1 genes and susceptibility in oral cancer. Dept. of Biotechnology, Govt. of India, 2001 – 2004.
    28. Human papillomavirus E6, E7 and p53 gene polymorphism in Indian cervical carcinoma. Indian Council for Medical Research, 2002 – 2004.
    29. Cellular and molecular manifestations of natural plant compounds on human papillomavirus infected cells. Indian Council for Medical Research, 2002 – 2004.
    30. Fund for Improvement of Science & Technology Infrastructure in Universities and Higher Educational Institutions. Dept of Science and Technology, 2000 – 2005.
    31. Ras gene mutation and tumor response to radiation therapy. Kerala State Committee for Science, Technology & Environment, 2003 – 2005.
    32. Cellular pharmacology of anti-tumor and anti-viral activity of curcumin against cervical cancer. Council of Scientific and Industrial Research, 2003 – 2006.
    33. Molecular markers for the detection and progression of cervical cancer. Department of Biotechnology, 2003 – 2006.
    34. The nutri-genomics of cervical cancer. Kerala State Council for Science, Technology and Environment, 2004 – 2007.
    35. Folate receptor, heterogenous ribonucleoprotein, human papillomavirus and epithelial tumor progression. Indian Council of Medical Research, 2005 – 2007.
    36. Development of human papillomavirus vaccine prototype/s - Molecular epidemiology of HPV types prevalent in India and identification of HPV-16 L1 & E6 variants. Department of Biotechnology, 2005 – 2008.
    37. Molecular analysis of surgical margins in oral carcinoma. Kerala State Council for Science, Technology and Environment, 2005 – 2008.
    38. Molecular evidence for Plumbagin as an anti-tumor and radiosensitizing agent in cervical cancer. Dept. of Atomic Energy, Govt. of India, 2005 – 2008.
    39. Pre-clinical development and molecular pharmacology of arsenic as an anti-tumor anti-viral agent in human papillomavirus associated cervical cancer. Dept of Science & Technology, Govt. of India, 2006 – 2009.
    40. Virtual Screening (Vs) and laboratory validation of antihuman papillomavirus compounds. Department of Biotechnology, 2006 – 2009.
    41. In silico identification and analysis of (CHIKV) inhibitors from natural product libraries based on E1 envelop protein structure. Department of Biotechnology, 2008 – 2009.
    42. Targeted anti-cancer lead discovery: Virtual screening of chemical libraries enriched in natural products. Department of Information Technology, 2007 – 2010.
    43. Prospective identification and clinical significance of tumor progenitor cells in oral and breast cancer. Department of Biotechnology, 2007 – 2010.
    44. Clinical and patho-biological effects of curcumin on oral leukoplakia: A double blind placebo controlled randomized trial. Department of Biotechnology, 2006 – 2010.
    45. Molecular ecology, molecular genetics and natural history of anterior tongue cancer in young adults without (or insignificant) tobacco exposure: can a distinct clinical entity be defined? Department of Biotechnology, 2007 – 2010.
    46. Differentiation of UCB stem cells into lineage specific cell types for therapeutic applications. Department of Biotechnology, 2008 – 2011.
    47. Tumor primordial cells in colorectal cancer: implications for surgical margins and minimal residual disease. Department of Biotechnology, 2008 – 2011.
    48. Prospecting Zingiber zerumpet for molecular resources. Department of Biotechnology, (2010-2013)
    49. Development of novel sensitizers based on NIR dyes: Metal based drug including leads from traditional medicine. Department of Science & Technology, 2007 - 2014.
    50. Computational biology for design of optimum vaccine candidates and development of quantum dot based diagnostics for classical swine fever virus. Department of Biotechnology, 2008 - 2014.
    51. Experimental studies on therapy of cancers expressing hCG/hCGB with a recombinant highly immunogenic vaccine against hCG. Department of Biotechnology, 2012 - 2014.
  • Publications

    Publications 2014 – 2015

    Total Research Publications: 204 (As on September , 2016)
    As Corresponding or Senior Author: 111; As First Author: 47; As Co-author: 46

    1. Muraleedharan Parvathy, Sreeharshan Sreeja, Rakesh Kumar and Madhavan Radhakrishna Pillai. Potential role of p21 Activated Kinase 1 (PAK1) in the invasion and motility of oral cancer cells. BMC Cancer. 2016 May 16;16 Suppl 1:293. doi: 10.1186/s12885-016-2263-8.
    2. Srinivas KP, Viji R, Dan VM, Sajitha IS, Prakash R, Rahul PV, Santhoshkumar TR, Lakshmi S, Pillai MR. DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. Oncotarget. 2016 Mar 16. doi: 10.18632/oncotarget.8131. [Epub ahead of print]
    3. Dr Rengaswamy Sankaranarayanan, Priya Ramesh Prabhu, Michael Pawlita, Tarik Gheit, Neerja Bhatla, Richard Muwonge, Bhagwan M Nene, Pulikottil Okuru Esmy, Smita Joshi, Usha Rani Reddy Poli, Parimal Jivarajani, Yogesh Verma, Eric Zomawia, Prof Maqsood Siddiqi, Prof Surendra S Shastri, Kasturi Jayant, Sylla G Malvi, Eric Lucas, Angelika Michel, Julia Butt, Janki Mohan Babu Vijayamma, Subha Sankaran, Thiraviam Pillai Rameshwari Ammal Kannan, Rintu Varghese, Uma Divate, Shila Thomas, Geeta Joshi, Martina Willhauck-Fleckenstein, Tim Waterboer, Martin Müller, Peter Sehr, Sanjay Hingmire, Prof Alka Kriplani, Gauravi Mishra, Sharmila Pimple, Radhika Jadhav, Catherine Sauvaget, Massimo Tommasino, Pillai MR. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. The Lancet Oncology. 1 December 2015, http://dx.doi.org/10.1016/S1470-2045(15)00414-3
    4. Rajaraman P, Dey B, Majumder PP, Mayor S, Pillai MR, Ramaswamy S, Shaha C, Johnson M, Sivaram S, Trimble EL, Harlow EE, VijayRaghavan K. First International Workshopson Provocative Questions (PQ) in Cancer Research, October-November 2014, New Delhi, Bengaluru, and Thiruvananthapuram, India, J Cancer Policy. 2015 Dec 1;6:33-36.
    5. Krishnan S, Dhillon PK, Bhadelia A3, Schurmann A, Basu P, Bhatla N, Birur P, Colaco R, Dey S, Grover S, Gupta H, Gupta R, Gupta V, Lewis MA, Mehrotra R, McMikel A, Mukherji A, Naik N, Nyblade L, Pati S, Pillai MR, Rajaraman P, Ramesh C, Rath GK, Reithinger R, Sankaranarayanan R, Selvam J, Shanmugam MS, Shridhar K, Siddiqi M, Squiers L, Subramanian S, Travasso SM, Verma Y, Vijayakumar M, Weiner BJ, Reddy KS, Knaul FM, Report from a symposium on catalyzing primary and secondary prevention of cancer in India. Cancer Causes Control. 2015 Nov;26(11):1671-84. doi: 10.1007/s10552-015-0637-x. Epub 2015 Sep 3.
    6. Azeez JM, Sithul H, Hariharan I, Sreekumar S, Prabhakar J, Sreeja S, Pillai MR. Progesterone regulates the proliferation of breast cancer cells – in vitro evidence, Drug Des Devel Ther. 2015 Nov 9;9:5987-5999.
    7. Das AV, Pillai MR. Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis, Cancer Cell Int. 2015 Sep 29;15:92. doi: 10.1186/s12935-015-0247-4. eCollection 2015
    8. Seetha Dayakar, Iravathy K. Goud, Heera Pillai, Viji Remadevi, Sanjai Dharmaseelan, Radhakrishnan R. Nair, Pillai MR. Molecular Diagnosis of Chikungunya virus (CHIKV) and Dengue virus (DENV) and its concomitant circulation in South Indian population, Virology Reports, 12 May 2015 doi:10.1016/j.virep.2015.05.001
    9. Ramakrishnan L, Pillai MR, Nair RR Dengue vaccine development: strategies and challenges. Viral Immunol. 2015 Mar;28(2):76-84. doi: 10.1089/vim.2014.0093. Epub 2014 Dec 10.
    10. HezlinMarzook*, Deivendran S*, Rakesh Kumar, Pillai MR. Role of MTA1 in Head and Neck cancer. Cancer and Metastasis Reviews, 33(4):953-64, December 2014
    11. Rajesh Raju, Aswathy Paul, Vivekanand Asokachandran, Bijesh George, Lekshmi Radhamony, Meena Vinaykumar, Reshmi Girijadevi, Pillai MR. The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data. Breast Cancer Research 2014, 16:490 (4 December 2014)
    12. S Deivendran, K Hezlin Marzook, Pillai MR. The role of inflammation in cervical cancer. Advances in Experimental Medicine and Biology ; 816:377-99, (2014)
    13. V C Dhanya, P J Sara, Dharmaselan Sanjai, Fetle Amar, P M Deepa, G R Santosh, V T Jisa and M R Pilai. Demographic and Clinical Characteristics of Pandemic Influenza A (H1N1) 2009 Outbreak in Kerala, Southern India. British Microbiology Research Journal 4(10): 142-153, 2014
    14. Zinia T. Nujum, Achu Thomas, K. Vijayakumar, Radhakrishnan R. Nair, Pillai MR, P S Indu, Syam Sundar, Soumya Gopakumar, Devi Mohan, T. K. Sudheeshkumar. Comparative performance of the probable case definitions of dengue by WHO (2009) and the WHO-SEAR expert group (2011) Pathogens and Global Health 2014, 108, Issue 2, pp. 103-110
    15. Paul Sebastian, Janki Mohan Babu, R Prathibha, Ramkumar Hariharan, and Pillai MR. Anterior tongue cancer with no history of tobacco and alcohol use may be a distinct molecular and clinical entity. Journal of Oral Pathology & Medicine 2014 (Online Version)
    16. Joshi, J.M. Babu, D. Jayalakshmi, V. Kulkarni, U. Divate, R. Muwonge,T.Gheit, M. Tommasino, R. Sankaranarayanan, Pillai MR. "Human papillomavirus infection among human immunodeficiency virus-infected women in Maharashtra, India." Vaccine 32 (2014) 1079- 1085.
    17. Ramachandran S, Venugopal A, Kutty VR, A V, G D, Chitrasree V, Mullassari A, Pratapchandran NS, Santosh KR, Pillai MR, Kartha CC. Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease. Cardiovasc Diabetol 13:38. doi: 10.1186/1475-2840-13-38, 2014.
  • Team


    Tumor Biology Program

    Sajitha I S, MVSc

    PhD student (in the Faculty Improvement Program, College of Veterinary Sciences)
    Multidrug resistance implies the insensitivity of a sub population of cancer cells to cytostatic and cytotoxic actions of various structurally and functionally unrelated chemotherapeutics. Such surviving cells will repopulate the original tumour causing local recurrence and distant metastasis. My work aims to study the kinetics of emergence of drug resistant cells after exposure to chemotherapeutics and its role in tumour recurrence. The study involves development of drug resistant cells from multiple cancer cell lines. The kinetics of tumour initiation in SCID mice is studied using both the parental and drug resistant cells, which will help us to understand the importance of such drug surviving cells in tumour recurrence and relapse.

    Dr.Sajitha-IS
    Dr.Sajitha-IS

    Sajitha I S, MVSc

    PhD student (in the Faculty Improvement Program, College of Veterinary Sciences)
    Multidrug resistance implies the insensitivity of a sub population of cancer cells to cytostatic and cytotoxic actions of various structurally and functionally unrelated chemotherapeutics. Such surviving cells will repopulate the original tumour causing local recurrence and distant metastasis. My work aims to study the kinetics of emergence of drug resistant cells after exposure to chemotherapeutics and its role in tumour recurrence. The study involves development of drug resistant cells from multiple cancer cell lines. The kinetics of tumour initiation in SCID mice is studied using both the parental and drug resistant cells, which will help us to understand the importance of such drug surviving cells in tumour recurrence and relapse.

    Rahul Sanawar, MTech

    PhD student

    My research topic is HER2 - FAM171A1 regulated signaling and its association with hormone receptor status during tumor progression and metastasis in breast cancer. Triple negative breast cancers are aggressive tumors with inherent increased invasion and metastasis properties coupled with non-responsiveness to current therapy. Both clinico-pathological and experimental studies have substantiated the major involvement of Her2 receptor in diverse signaling pathways associated with the aggressive phenotype. Hence it is critical to understand the role of Her2 and its downstream signaling both in hormone receptor positive and hormone receptor negative cancer types. Preliminary available data to address this key question revealed that Her2 drives expression several critical regulators of invasion and aggressiveness in basal type cells. A prominent protein identified from this screen is FAM171A1, a single-pass type 1 membrane protein. The functional role of FAM171A1 in tumor initiation or progression is not well understood although recent microarray data from primary breast tumors suggest that FAM171A1 is associated with increased invasion and metastasis. Hence the primary focus of my work is to understand which signaling events are critically influenced by HER2 driven FAM171A1 during tumor progression and invasion in breast cancers.

    Rahul
    Rahul

    Rahul Sanawar, MTech

    PhD student

    My research topic is HER2 - FAM171A1 regulated signaling and its association with hormone receptor status during tumor progression and metastasis in breast cancer. Triple negative breast cancers are aggressive tumors with inherent increased invasion and metastasis properties coupled with non-responsiveness to current therapy. Both clinico-pathological and experimental studies have substantiated the major involvement of Her2 receptor in diverse signaling pathways associated with the aggressive phenotype. Hence it is critical to understand the role of Her2 and its downstream signaling both in hormone receptor positive and hormone receptor negative cancer types. Preliminary available data to address this key question revealed that Her2 drives expression several critical regulators of invasion and aggressiveness in basal type cells. A prominent protein identified from this screen is FAM171A1, a single-pass type 1 membrane protein. The functional role of FAM171A1 in tumor initiation or progression is not well understood although recent microarray data from primary breast tumors suggest that FAM171A1 is associated with increased invasion and metastasis. Hence the primary focus of my work is to understand which signaling events are critically influenced by HER2 driven FAM171A1 during tumor progression and invasion in breast cancers.

    Deepthi Prasad, MSc

    PhD student

    Cancer of the uterine cervix is the third most common cancer among women worldwide, and the second most amongst Indian women. It has an incidence of 22.9% and a mortality of 20.7% among Indian women suffering from cancer (GLOBOCAN, 2012). Cervical cancer usually begins as a pre-cancerous, benign lesion that could progress into dysplasia of increasing severity that eventually culminates in carcinogenesis. Human Papilloma Virus (HPV) is a known etiological agent for development of cervical cancer. Among the various types of HPV that infect the genital tract, the high-risk HPV types (predominantly types 16 and 18 in India) are known to be oncogenic. Although the integration of the viral genome into the host genome is essential for the carcinogenic transformation of the cervical epithelial cells, it is not sufficient. A variety of cofactors and molecular mechanisms, such as smoking, parity, use of oral contraceptives and nutritional status, may also influence the development of cervical cancer. This work has been designed to study the effect of micronutrient deficiency on the progression of HPV infection of the cervix into carcinoma.

    Deepthi-Prasad
    Deepthi-Prasad

    Deepthi Prasad, MSc

    PhD student

    Cancer of the uterine cervix is the third most common cancer among women worldwide, and the second most amongst Indian women. It has an incidence of 22.9% and a mortality of 20.7% among Indian women suffering from cancer (GLOBOCAN, 2012). Cervical cancer usually begins as a pre-cancerous, benign lesion that could progress into dysplasia of increasing severity that eventually culminates in carcinogenesis. Human Papilloma Virus (HPV) is a known etiological agent for development of cervical cancer. Among the various types of HPV that infect the genital tract, the high-risk HPV types (predominantly types 16 and 18 in India) are known to be oncogenic. Although the integration of the viral genome into the host genome is essential for the carcinogenic transformation of the cervical epithelial cells, it is not sufficient. A variety of cofactors and molecular mechanisms, such as smoking, parity, use of oral contraceptives and nutritional status, may also influence the development of cervical cancer. This work has been designed to study the effect of micronutrient deficiency on the progression of HPV infection of the cervix into carcinoma.

    Human Papillomavirus Research Program

    Priya R Prabhu, MSc

    PhD student

    The HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC) has participants who have received one, two and three vaccine doses with varying window periods in between the doses and collection of their plasma samples at defined time points after vaccination. My study looks at intermediate endpoints of the trial namely the sero-conversion status and its correlation with vaccine doses received. I also study avidity indices that are a surrogate marker for the generation of memory B cells and thereby achieving a long-term immunological memory. We do this by the differences in avidity, neutralization and cross-neutralization of HPV L1 antibodies after Gardasil vaccination with varying dose and time schedules. In addition I also do a serological survey of the HPV infections (frequency of serum antibodies to HPV 16 E6 and also early proteins E1, E2, E7) in oro-pharyngeal cancers to better elucidate their natural history and disclose antigen determinants useful for early diagnosis and vaccine development.

    priya-r-prabhu
    priya-r-prabhu

    Priya R Prabhu, MSc

    PhD student

    The HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC) has participants who have received one, two and three vaccine doses with varying window periods in between the doses and collection of their plasma samples at defined time points after vaccination. My study looks at intermediate endpoints of the trial namely the sero-conversion status and its correlation with vaccine doses received. I also study avidity indices that are a surrogate marker for the generation of memory B cells and thereby achieving a long-term immunological memory. We do this by the differences in avidity, neutralization and cross-neutralization of HPV L1 antibodies after Gardasil vaccination with varying dose and time schedules. In addition I also do a serological survey of the HPV infections (frequency of serum antibodies to HPV 16 E6 and also early proteins E1, E2, E7) in oro-pharyngeal cancers to better elucidate their natural history and disclose antigen determinants useful for early diagnosis and vaccine development.

    Subha Sankaran, MCA

    Data Manager (HPV research facility)

    I look after database management of the central human sample storage facility at the IARC-WHO HPV vaccine efficacy test center. My work includes storage, appropriate retrieval and data management of the samples received from all collaborating centers in India.

    Subha
    Subha

    Subha Sankaran, MCA

    Data Manager (HPV research facility)

    I look after database management of the central human sample storage facility at the IARC-WHO HPV vaccine efficacy test center. My work includes storage, appropriate retrieval and data management of the samples received from all collaborating centers in India.

    Rintu Varghese, MSc

    Technical Assistant

    I provide technical assistance for the project "Accurate and satisfactory analysis of all high risk HPV types and some low risk type antibody titers for the 2 verses 3 dose HPV vaccination clinical trial in India". In addition I also operate and perform analysis for RGCB's transmission electron microscope including imaging, sample preparation, operation and maintenance.

    Rintu-Varghese
    Rintu-Varghese

    Rintu Varghese, MSc

    Technical Assistant

    I provide technical assistance for the project "Accurate and satisfactory analysis of all high risk HPV types and some low risk type antibody titers for the 2 verses 3 dose HPV vaccination clinical trial in India". In addition I also operate and perform analysis for RGCBs transmission electron microscope including imaging, sample preparation, operation and maintenance.

    Jinu Austin

    Laboratory Assistant

    My work includes maintenance and retrieval of patient's samples in the WHO/IARC storage facility as well as other laboratory support required for the experiments.

    Jinu-Austin
    Jinu-Austin

    Jinu Austin

    Laboratory Assistant

    My work includes maintenance and retrieval of patient's samples in the WHO/IARC storage facility as well as other laboratory support required for the experiments.

    Edwin S

    Senior Technical Assistant

    I look after general laboratory management and coordination of the laboratories with the RGCB central stores, RGCB purchase and RGCB administration. I am also involved in the management of the RGCB cafeteria and catering services.

    lekshmi4 - Copy
    lekshmi4 - Copy

    Edwin S

    Senior Technical Assistant

    I look after general laboratory management and coordination of the laboratories with the RGCB central stores, RGCB purchase and RGCB administration. I am also involved in the management of the RGCB cafeteria and catering services.

    Computational Biology & Bioinformatics Program

    Rajesh Raju, PhD

    Post Doctoral Associate

    My research focuses on the development of ligand-receptor signaling system models as a platform for analysis of cross-talk and spatio-temporal dynamics of cellular signaling. Cell signaling pathways are essential gateways to systems biology. Individual ligand-receptor signaling pathways are often studied as distinct system(s). In fact, they are part of the large dynamic network of reactions that mediate and direct the cellular functions. Lineation of the reactions induced by the stimulation of individual receptors and integration of cross-talking networks of the intracellular signaling modules and those that are imparted by subsequent extracellular stimuli could be instrumental in deriving the topological features of such networks. These network(s) could then be analyzed for the spatio-temporal dynamicity to extract biological relevance from the snapshots of transcriptomics, proteomics and other omics data obtained from high-throughput technologies.

    rajesh
    rajesh

    Rajesh Raju, PhD

    Post Doctoral Associate

    My research focuses on the development of ligand-receptor signaling system models as a platform for analysis of cross-talk and spatio-temporal dynamics of cellular signaling. Cell signaling pathways are essential gateways to systems biology. Individual ligand-receptor signaling pathways are often studied as distinct system(s). In fact, they are part of the large dynamic network of reactions that mediate and direct the cellular functions. Lineation of the reactions induced by the stimulation of individual receptors and integration of cross-talking networks of the intracellular signaling modules and those that are imparted by subsequent extracellular stimuli could be instrumental in deriving the topological features of such networks. These network(s) could then be analyzed for the spatio-temporal dynamicity to extract biological relevance from the snapshots of transcriptomics, proteomics and other omics data obtained from high-throughput technologies.

    Aswathy Mary Paul, MSc

    PhD student

    My work is on Integrative Computational Analysis to explore microRNA-mediated regulatory networks in HPV mediated cervical cancer. The focus of studies is to develop a computational approach to construct a miRNA-TF regulatory network to identify potential targets that may have value for early detection or prognostic markers of human cervical cancer. We systematically explore the main regulation format (feed-forward loops, FFLs) consisting of miRNAs, transcription factors (TFs) and their impacting cervical cancer related genes. We hope that this study will allow us to integrate the data sets with genetic mapping information, predicted and established gene functional role classifications, metabolic pathway assignments and metabolic profiling patterns.

    Aswathy-Mary-Paul
    Aswathy-Mary-Paul

    Aswathy Mary Paul, MSc

    PhD student

    My work is on Integrative Computational Analysis to explore microRNA-mediated regulatory networks in HPV mediated cervical cancer. The focus of studies is to develop a computational approach to construct a miRNA-TF regulatory network to identify potential targets that may have value for early detection or prognostic markers of human cervical cancer. We systematically explore the main regulation format (feed-forward loops, FFLs) consisting of miRNAs, transcription factors (TFs) and their impacting cervical cancer related genes. We hope that this study will allow us to integrate the data sets with genetic mapping information, predicted and established gene functional role classifications, metabolic pathway assignments and metabolic profiling patterns.

    Bijesh George, MSc

    Senior Research Fellow

    We are working on developing a model to forecast the outbreak of Dengue virus in Kerala: creating a freely accessible web resource. The study focuses on developing a comprehensive and flexible disease predictive modeling tool based on machine learning methods, which will be aimed at planning the future needs of public health and detecting surveillance monitoring to forewarn of disease outbreaks. Further extend this into a more utility-added web resource by providing simple bioinformatics tools and analyzes that can be run, based on the data held in the internal database. The proposed model and tool will be useful to policymakers, public health workers and other researchers who want to better understand and respond to emerging infectious diseases.

    bijesh
    bijesh

    Bijesh George, MSc

    Senior Research Fellow

    We are working on developing a model to forecast the outbreak of Dengue virus in Kerala: creating a freely accessible web resource. The study focuses on developing a comprehensive and flexible disease predictive modeling tool based on machine learning methods, which will be aimed at planning the future needs of public health and detecting surveillance monitoring to forewarn of disease outbreaks. Further extend this into a more utility-added web resource by providing simple bioinformatics tools and analyzes that can be run, based on the data held in the internal database. The proposed model and tool will be useful to policymakers, public health workers and other researchers who want to better understand and respond to emerging infectious diseases.

    Meena Vinaykumar, MCA

    System Analyst

    My duties include managing, maintaining, developing and deploying websites, web applications and databases in response to needs of Cancer Research Lab . I am also involved in database administration and development, adding functionality to existing databases in production, maintenance and updates of existing websites and applications

    Meena-Vinay
    Meena-Vinay

    Meena Vinaykumar, MCA

    System Analyst

    My duties include managing, maintaining, developing and deploying websites, web applications and databases in response to needs of Cancer Research Lab . I am also involved in database administration and development, adding functionality to existing databases in production, maintenance and updates of existing websites and applications

    Vishnu V M, B.Sc

    Research Assistant

    My duties mainly in assisting research scholars for data collection, documentation and facilitation of research work besides organizing various seminars and workshops related to specific research areas.

    Vishnu vm
    Vishnu vm

    Vishnu V M, B.Sc

    Research Assistant

    My duties mainly in assisting research scholars for data collection, documentation and facilitation of research work besides organizing various seminars and workshops related to specific research areas.

  • Alumni


    Dr. S Lakshmi

    Associate Professor
    Molecular Medicine
    Regional Cancer Centre
    Trivandrum
    Phone: +91 471 2522280 (O)

    dr.lekshmi
    dr.lekshmi

    Dr. S Lakshmi

    Associate Professor
    Molecular Medicine
    Regional Cancer Centre
    Trivandrum
    Phone: +91 471 2522280 (O)

    Dr. Asha S Nair

    Scientist E-II
    Cancer Research
    Rajiv Gandhi Centre for Biotechnology

    asha
    asha

    Dr. Asha S Nair

    Scientist E-II
    Cancer Research
    Rajiv Gandhi Centre for Biotechnology

    Dr. A. Lakshmi Kesari

    Senior Lecturer & Coordinator GRU
    General Requirements Program (GRU)
    Fatima College of Health Sciences
    Al Ain, UAE
    Office: 971 (03)7035418
    Mobile: 0504100534
    Email: lakshmi.ambika@fchs.ac.ae

    kesari
    kesari

    Dr. A. Lakshmi Kesari

    Senior Lecturer & Coordinator GRU
    General Requirements Program (GRU)
    Fatima College of Health Sciences
    Al Ain, UAE
    Office: 971 (03)7035418
    Mobile: 0504100534
    Email: lakshmi.ambika@fchs.ac.ae

    Dr. R. Radhakrishnan

    Scientist E-I
    Laboratory Medicine And Molecular Diagnostics
    Rajiv Gandhi Centre for Biotechnology

    radhakrishnan
    radhakrishnan

    Dr. R. Radhakrishnan

    Scientist E-I
    Laboratory Medicine And Molecular Diagnostics
    Rajiv Gandhi Centre for Biotechnology

    Dr. Srinivas G

    Scientist E
    Sree Chitra Tirunal Institute for Medical Sciences & Technology
    Trivandrum
    Phone: 471 2524689 (O), 2347918 (H), 8547547918 (Mob)
    Email: srinivasg@sctimst.ac.in; srinivasgpai@gmail.com

    srini
    srini

    Dr. Srinivas G

    Scientist E
    Sree Chitra Tirunal Institute for Medical Sciences & Technology
    Trivandrum
    Phone: 471 2524689 (O), 2347918 (H), 8547547918 (Mob)
    Email: srinivasg@sctimst.ac.in; srinivasgpai@gmail.com

    Dr. Pradip Nair

    Senior Scientific Manager
    Drug Discovery group
    R&D, Biocon India Limited, Bangalore
    Mob: 9945073336
    Email: pradip.nair@biocon.com

    pradip
    pradip

    Dr. Pradip Nair

    Senior Scientific Manager
    Drug Discovery group
    R&D, Biocon India Limited, Bangalore
    Mob: 9945073336
    Email: pradip.nair@biocon.com

    Dr. Sreevidya S

    sreevidya
    sreevidya

    Dr. Sreevidya S

    Dr. Priya Chacko

    Postdoctoral Fellow
    LV Prasad Eye Institute
    Hyderabad

    priya
    priya

    Dr. Priya Chacko

    Postdoctoral Fellow
    LV Prasad Eye Institute
    Hyderabad

    Dr. Thomas Joseph

    Senior Scientist
    TCS Innovation Labs
    Tata Consultancy Services

    thomas
    thomas

    Dr. Thomas Joseph

    Senior Scientist
    TCS Innovation Labs
    Tata Consultancy Services

    Dr. Bindhu O S

    Assistant Professor
    Dept of Biochemistry
    Centre for Post Greaduate Studies
    Jain University, Bangalore
    Mob: 9845084899
    Email: bindhupradip@yahoo.co.in
    os.bindhu@jainuniversity.ac.in

    bindhu
    bindhu

    Dr. Bindhu O S

    Assistant Professor
    Dept of Biochemistry
    Centre for Post Greaduate Studies
    Jain University, Bangalore
    Mob: 9845084899
    Email: bindhupradip@yahoo.co.in
    os.bindhu@jainuniversity.ac.in

    Dr. Divya Chandrasekhar

    divya
    divya

    Dr. Divya Chandrasekhar

    Dr. Sreekala Nair

    Senior Research Scientist B
    Jubilant Biosys
    Bangalore

    sreekala
    sreekala

    Dr. Sreekala Nair

    Senior Research Scientist B
    Jubilant Biosys
    Bangalore

    Dr. Ramkumar Hariharan

    Research Scientist
    Institute for Systems Biology
    Seattle, WA, USA

    ramkumar
    ramkumar

    Dr. Ramkumar Hariharan

    Research Scientist
    Institute for Systems Biology
    Seattle, WA, USA

    Dr. Surya Ramachandran

    Program Scientist
    Cardiovascular Disease Biology
    Rajiv Gandhi Centre for Biotechnology

    surya
    surya

    Dr. Surya Ramachandran

    Program Scientist
    Cardiovascular Disease Biology
    Rajiv Gandhi Centre for Biotechnology

    Dr. Santhi W S

    Assistant Professor of Biotechnology
    Department of Botany and Biotechnology
    Bishop Moore College
    Mavelikara 690110
    Kerala, India

    santhi
    santhi

    Dr. Santhi W S

    Assistant Professor of Biotechnology
    Department of Botany and Biotechnology
    Bishop Moore College
    Mavelikara 690110
    Kerala, India

    Dr. Preeti N R

    Senior Project Coordinator
    WHO Program on Pediatric Nutrition
    Christian Medical College
    Vellore

    preethi
    preethi

    Dr. Preeti N R

    Senior Project Coordinator
    WHO Program on Pediatric Nutrition
    Christian Medical College
    Vellore

    Dr. Reshmi G

    Research Scientist I (ICMR)
    Rajiv Gandhi Centre for Biotechnology

    reshmi
    reshmi

    Dr. Reshmi G

    Research Scientist I (ICMR)
    Rajiv Gandhi Centre for Biotechnology

    Dr. Indhu Hariharan

    indu
    indu

    Dr. Indhu Hariharan

    Dr. Vinitha Richard

    vinitha
    vinitha

    Dr. Vinitha Richard

    Dr.Ramdas K

    Professor, Chief
    Head & Neck Cancer Clinic
    Medical Superintendent
    Regional Cancer Centre
    Trivandrum

    ramdas
    ramdas

    Dr.Ramdas K

    Professor, Chief
    Head & Neck Cancer Clinic
    Medical Superintendent
    Regional Cancer Centre
    Trivandrum